Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete If Known	
Application Number	10/723,247
Filing Date	November 25, 2003
First Named Inventor	BAR-OR
Art Unit	~~1632~~ 1653
Examiner Name	Not Yet Assigned
Attorney Docket Number	4172-82

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number / Number-kind Code [2 (if known)]	Publication Date MM-DD-YYYY	Name of Patentee of Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document — Country Code[3]; Number[4]; Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		-				
		-				
		-				
		-				
		-				

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

Examiner Initials*	Cite No.[1]	
SL	1	Takeishi et al.; "In Vivo Phosphorylation of Cardiac Troponin I by Protein Kinase Cβ2 Decreases Cardiomyocyte Calcium Responseiveness and Contractility in Transgenic Mouse Hearts"; *J. Clin. Invest.*; July 1998; 102(1):72-78

Examiner Sigature	/Samuel Liu/	Date Considered	05/02/2006

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

J:\4172\-82\1449-002.wpd

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 4172-82	SERIAL NO. 10/723,247
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	APPLICANT Bar-Or	
	FILING DATE November 25, 2003	GROUP ART 1653

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
SL	A1.	6,355,297	3/12/2002	Sawatzki et al.	426	657	
	A2.	6,355,297	3/12/2002	Sawatzki et al.	426	657	
	A3.	6,329,155	12/11/2001	Nitsch et al.	435	7.21	
	A4.	6,270,827	8/7/2001	Gaull et al.	426	580	
	A5.	6,268,194	7/31/2001	Karin et al.	435	194	
	A6.	6,242,253	6/5/2001	Karin et al.	435	325	
	A7.	6,232,094	5/15/2001	Hansson et al.	435	069.1	
	A8.	6,147,080	11/14/2000	Bemis et al	514	258	
	A9.	6,093,742	7/25/2000	Salituro et al.	514	596	
	A10.	5,952,295	9/14/1999	Arnaud-Battandier et al.	514	2	
	A11.	5,945,418	8/31/1999	Bemis et al.	514	248	
	A12.	5,942,274	8/24/1999	Slattery	426	580	
	A13.	5,932,580	8/3/1999	Levitzki et al.	514	249	
	A14.	5,902,786	5/11/1999	Bregman	514	2	
	A15.	5,795,611	8/18/1998	Slattery	426	580	
	A16.	5,739,407	4/14/1998	Bergstrom et al.	800	007	
	A17.	5,583,221	12/10/1996	Hu et al.	540	520	
SL	A18.	5,432,198	7/11/1995	Jagdmann, Jr.	514	544	

EXAMINER /Samuel Liu/	DATE CONSIDERED 05/02/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 4172-82	SERIAL NO. 10/723,247
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	APPLICANT Bar-Or	
	FILING DATE November 25, 2003	GROUP ART

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
SL	A19.	5,385,915	1/31/1995	Buxbaum et al.	514	313	
	A20.	5,352,476	10/4/1994	Brule et al.	426	657	
	A21.	5,344,841	9/6/1994	Jiang et al.	514	459	
	A22.	5,334,408	8/2/1994	Brule et al.	426	57	
	A23.	5,292,737	3/8/1994	Defauw	514	247	
	A24.	5,279,814	1/18/1994	Wuelknitz et al.	424	52	
	A25.	5,270,310	12/14/1993	Bell et al.	514	238.2	
	A26.	5,216,014	6/1/1993	Jiang et al.	514	455	
	A27.	5,204,370	4/20/1993	Jiang et al.	514	475	
	A28.	5,189,046	2/23/1993	Burch et al.	514	330	
	A29.	5,141,957	8/25/1992	Jiang et al.	514	510	
	A30.	5,130,123	7/14/1992	Reynolds et al.	424	49	
	A31.	5,068,118	11/26/1991	Strandholm	426	582	
	A32.	4,777,243	10/11/1988	Jolles et al.	530	300	
	A33.	4,462,990	7/31/1984	Jolles et al.	424	177	
	A34.	4,419,369	12/6/1983	Nichols et al.	426	002	
	A35.	4,358,465	11/9/1982	Brule et al.	435	068.1	
	A36.	4,284,623	8/18/1981	Beck	424	85	
	A37.	3,966,915	6/29/1976	Caprino	424	177	
SL	A38.	3,901,979	8/26/1975	Nagasawa et al.	426	613	

EXAMINER	/Samuel Liu/	DATE CONSIDERED	05/02/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 4172-82	SERIAL NO. 10/723,247
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	APPLICANT Bar-Or	
	FILING DATE November 25, 2003	GROUP ART

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
SL	A39.	3,558,770	1/26/1971	Gordon et al.	424	80	
SL	A40.	2001/0025044 A1	9/27/2001	Salituro et al.	514	259	12/11/2000

FOREIGN PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY				
SL	A41.	WO 02/04949	1/17/02	PCT				
	A42.	JP 2001/0107122 A2	1/23/2001	Japan				
	A43.	WO 01/22837 A1	4/5/2001	PCT				
	A44.	JP 10203996 A2	8/4/1998	Japan				
	A45.	EP 0862450 A2	9/9/1998	EPO				
	A46.	EP 0760674 A1	2/12/1997	EPO				
	A47.	WO 96/06530	3/17/1996	PCT				
	A48.	EP 0 699 444 A2	306/1996	EPO				
	A49.	JP 5025032 A2	2/2/1993	Japan				
	A50.	WO 92/18526	10/29/1992	PCT				
SL	A51.	JP 3056500 A2	3/12/1991	Japan				

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

SL	A52.	Aitken, Protein consensus sequence motifs, *Mol Biotechnol* 1999, 12(3):241-53, Abstract only, from PubMed - PMID:10631681

EXAMINER /Samuel Liu/	DATE CONSIDERED 05/02/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 4172-82	SERIAL NO. 10/723,247
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	APPLICANT Bar-Or	
	FILING DATE November 25, 2003	GROUP ART

SL	A53.	Casein Kinase II Peptide Substrate. Datasheet [online]. Promega Corporation, 2003 [retrieved on 11/25/2003]. Retrieved from the Internet: <URL:http://www.promega.com/catalog/CatalogProducts.asp?catalog%5Fname=Promega%5FP...
	A54.	Casein Kinase I Peptide Substrate. Datasheet [online]. Promega Corporation, 2003 [retrieved on 11/19/2003]. Retrieved from the Internet: <URL:http://www.promega.com/catalog/CatalogProducts.asp?catalog%5Fname=Promega%5FP...
	A55.	Casein Kinase I Peptide Substrate. Datasheet [online]. Promega Corporation, 2003 [retrieved on 11/25/2003]. Retrieved from the Internet: <URL:http://www.promega.com/catalog/CatalogProducts.asp?catalog%5Fname=Promega%5FP...
	A56.	cdc2 Protein Kinase Peptide Substrate. Datasheet [online]. Promega Corporation, 2003 [retrieved on 11/25/2003]. Retrieved from the Internet: <URL:http://www.promega.com/catalog/CatalogProducts.asp?catalog%5Fname=Promega%5FP...
	A57.	cGMP-Dependent Protein Kinase (PKG) Peptide Substrate. Datasheet [online]. Promega Corporation, 2003 [retrieved on 11/25/2003]. Retrieved from the Internet: <URL:http://www.promega.com/catalog/CatalogProducts.asp?catalog%5Fname=Promega%5FP...
	A58.	Cohen et al., The development and therapeutic potential of protein kinase inhibitors, *Current Opinion in Chemical Biology* 1999, 3:459-465
	A59.	DNA-Dependent Protein Kinase Peptide Substrate. Datasheet [online]. Promega Corporation, 2003 [retrieved on 11/25/2003]. Retrieved from the Internet: <URL:http://www.promega.com/catalog/CatalogProducts.asp?catalog%5Fname=Promega%5FP...
	A60.	Hata et al., Identification of a phosphopeptide in bovine α_{s1}-casein digest as factor influencing proliferation and immunoglobulin production in lymphocyte cultures, *Journal of Sairy Research* 1998 65:569-578
	A61.	Jiang et al., Preparation of novel functional oligophosphopeptides from hen egg yolk phosvitin, *J. Agric Food Chem* 2000, 48(4):990-994, **Abstract only**, from PubMed - PMID:10775339
	A62.	Jourd'heuil et al., Oxidant-regulation of gene expression in the chronically inflamed intestine, *Keio J. Med.* 1997, 46(1):10-15, **Abstract only**, from PubMed - PMID:9095577
	A63.	Kemptide (PKA) Peptide Substrate. Datasheet [online]. Promega Corporation, 2003 [retrieved on 11/25/2003]. Retrieved from the Internet: <URL:http://www.promega.com/catalog/CatalogProducts.asp?catalog%5Fname=Promega%5FP...
	A64.	Kreegipuu et al., PhosphoBase, a database of phosphorylation sites: release 2.0, *Nucleic Acids Research* 1999, 27(1):237-239
	A65.	Lee et al., Inhibition of p38 MAP kinase as a therapeutic strategy, *Immunopharmacology* 2000, 47(2):185-201, **Abstract only**, from PubMed - PMID:10878289
SL	A66.	Lee et al., Antioxidant Activity of Phosvitin in Phosphatidylcholine Liposomes and Meat Model Systems, *J. of Food Science* 2002, 67(1), **Abstract only**

EXAMINER	/Samuel Liu/	DATE CONSIDERED	05/02/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 4172-82	SERIAL NO. 10/723,247
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	APPLICANT Bar-Or	
	FILING DATE November 25, 2003	GROUP ART

SL	A67.	Miller et al., Dephosphorylation of chicken riboflavin-binding protein and phosvitin decreases their uptake by oocytes, *Journal of Biological Chemistry* 1982, **257**(12):6818-6824
	A68.	Neurogranin$_{(28-43)}$ (PKC) Peptide Substrate. Datasheet [online]. Promega Corporation, 2003 [retrieved on 11/25/2003]. Retrieved from the Internet: <URL:http://www.promega.com/catalog/CatalogProducts.asp?catalog%5Fname=Promega%5FP...
	A69.	PhosphoBase v2.0, A database of phosphorylation sites, provided by Center for Biological Sequence Analysis (CBS) [online] [retrieved on 11/26/2002]. Retrieved from the Internet:<URL:http://www.cbs.dtu.dk/databases/PhosphoBase/
	A70.	Phosphoprotein Database (PPDB), Introduction to the phosphoprotein database* [online] [retrieved on 11/26/2002]. Retrieved from the Internet:<URL:http://www-lmmb.ncifcrf.gov/phosphoDB/
	A71.	Shanley, Phosphates: counterregulatory role in inflammatory cell signaling, *Crit Care Med* 2002, 30(1)(Suppl.):S80-S88
	A72.	Songyang et al., Use of an oriented peptide library to determine the optimal substrates of protein kinases, *Curr Biol.* 1994, 4(11):973-982, **Abstract only**, from PubMed - PMID:7874496
	A73.	Worthington Casein, Alpha, Manual Page, Worthington-biochem.com [online] [retrieved on 11/20/2003]. Retrieved from the Internet:<URL:http://www.worthington-biochem.com/CASA/default.html
SL	A74.	Wu et al., Identifying substrate motifs of protein kinases by a random library approach, *Biochemistry* 1994, 33(49):14825-33, **Abstract only**, from PubMed - PMID:7993909

EXAMINER /Samuel Liu/	DATE CONSIDERED 05/02/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.